{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:06:42Z","timestamp":1786115202533,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Faculty of Health Sciences, North-West University, South Africa"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Substance use disorder (SUD) is a debilitating neuropsychiatric condition characterized by persistent compulsive drug use and associated cognitive and psychiatric impairments. Emerging evidence suggests that neuroinflammatory pathways contribute to the pathophysiology of SUD. However, the relationships between neuroinflammatory-related biomarkers and psychiatric symptomatology in SUD remain poorly understood. This study aimed to investigate neuroinflammatory-related biomarkers and their association with psychiatric symptom changes in individuals with SUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants with SUD (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009100) at three local facilities in the North West Province of South Africa were enrolled. At baseline and following three weeks of treatment, psychiatric symptoms were assessed using the Brief Psychiatric Rating Scale (BPRS). Serum levels of superoxide dismutase (SOD), glutathione (GSH), glutathione disulphide (GSSG), tryptophan, kynurenine (KYN), kynurenic acid (KYNA), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), cortisol and serum S100 calcium-binding protein B (S100B) were measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over the 3-week treatment period BPRS scores and serum levels of tryptophan, 5-HT, 5-HIAA, KYN, KYNA, cortisol and GSH decreased, whereas SOD, S100B and GSSG levels increased. Baseline BPRS correlated with baseline serum levels of 5-HIAA, KYNA and GSSG. A decrease in BPRS correlated with baseline levels of 5HIAA, KYN and KYNA, as well as with 3-week changes in levels of select biomarkers (\u2206tryptophan, \u22065-HT, \u22065-HIAA, \u2206KYN, \u2206KYNA, \u2206GSSG and \u2206cortisol).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results suggest that baseline 5-HIAA, KYN and KYNA may predict psychiatric symptom improvement whereas tryptophan, 5-HT, 5-HIAA, KYN, KYNA, GSSG and cortisol may explain the neurobiological basis of changed psychiatric symptomatology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-08237-0","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:13:57Z","timestamp":1780132437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroinflammatory-related biomarkers and psychiatric symptom changes in substance use disorder: a South African cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Alexio","family":"Dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan B.","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esm\u00e9","family":"Jansen van Vuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"8237_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-019-0204-7","volume":"14","author":"BX Tran","year":"2019","unstructured":"Tran BX, Moir M, Latkin CA, Hall BJ, Nguyen CT, Ha GH, Nguyen NB, Ho CS, Ho RC. Global research mapping of substance use disorder and treatment 1971\u20132017: implications for priority setting. Subst Abuse Treat Prev Policy. 2019;14:1\u201314.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"8237_CR2","doi-asserted-by":"crossref","unstructured":"Merz F. United Nations Office on Drugs and Crime: World Drug Report 2017. SIRIUS-Zeitschrift f\u00fcr Strategische Analysen. 2018;2(1):85-86.","DOI":"10.1515\/sirius-2018-0016"},{"key":"8237_CR3","unstructured":"UNODC. World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8). 2021."},{"issue":"10100","key":"8237_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","volume":"390","author":"SI Hay","year":"2017","unstructured":"Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260\u2013344.","journal-title":"Lancet"},{"key":"8237_CR5","unstructured":"World Health Organization (WHO). Disease burden and mortality estimates: cause-specific mortality 2000\u20132016. Geneva: World Health Organization; 2018."},{"key":"8237_CR6","unstructured":"Dada S, Harker Burnhams N, Erasmus J, Lucas W, Parry C, Bhana A, Pretorius S, Weimann R, Keen R. Monitoring alcohol, tobacco and other drug abuse treatment admissions in South Africa. SACENDU (South Afr Community Epidemiol Netw Drug Use). 2018 Apr:1-72."},{"key":"8237_CR7","unstructured":"Dada S, Harker Burnhams N, Erasmus J, Warren L, Parry C, Bhana A, Pretorius S, Weimann R. Monitoring alcohol, tobacco, and other drug abuse treatment admissions in South Africa. Phase 48 ed. South African Community Epidemiology Network on Drug Use; 2021."},{"key":"8237_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-018-0167-0","volume":"13","author":"M Stokes","year":"2018","unstructured":"Stokes M, Schultz P, Alpaslan A. Narrating the journey of sustained recovery from substance use disorder. Subst Abuse Treat Prev Policy. 2018;13:1\u201312.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"8237_CR9","first-page":"1097","volume":"98","author":"JO Merrill","year":"2014","unstructured":"Merrill JO, Duncan MH. Addiction disorders. Med Clin. 2014;98(5):1097\u2013122.","journal-title":"Med Clin"},{"key":"8237_CR10","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR. 5th ed. 2023."},{"key":"8237_CR11","unstructured":"Johnson SL. Therapist\u2019s guide to substance abuse intervention. Elsevier; 2003."},{"issue":"4","key":"8237_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMra1511480","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363\u201371.","journal-title":"N Engl J Med"},{"issue":"8","key":"8237_CR13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1176\/appi.ajp.2007.05030503","volume":"164","author":"G Koob","year":"2007","unstructured":"Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry. 2007;164(8):1149\u201359.","journal-title":"Am J Psychiatry"},{"key":"8237_CR14","volume-title":"Neuropathology of drug addictions and substance misuse volume 1: foundations of understanding, tobacco, alcohol","author":"VR Preedy","year":"2016","unstructured":"Preedy VR. Neuropathology of drug addictions and substance misuse volume 1: foundations of understanding, tobacco, alcohol. cannabinoids and opioids: Academic; 2016."},{"issue":"3","key":"8237_CR15","doi-asserted-by":"publisher","first-page":"e0213791","DOI":"10.1371\/journal.pone.0213791","volume":"14","author":"N Garc\u00eda-Marchena","year":"2019","unstructured":"Garc\u00eda-Marchena N, Barrera M, Mestre-Pint\u00f3 JI, Araos P, Serrano A, P\u00e9rez-Ma\u00f1\u00e1 C, Papaseit E, Fonseca F, Ruiz JJ, Rodr\u00edguez de Fonseca F. Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. PLoS ONE. 2019;14(3):e0213791.","journal-title":"PLoS ONE"},{"issue":"4","key":"8237_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000442046","volume":"22","author":"H Bayazit","year":"2016","unstructured":"Bayazit H, Cicek E, Selek S, Aksoy N, Karababa IF, Kandemir H, Basmaci Kandemir S. Increased S100B levels in cannabis use disorder. Eur Addict Res. 2016;22(4):177\u201380.","journal-title":"Eur Addict Res"},{"issue":"9","key":"8237_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/antiox9090830","volume":"9","author":"P Berr\u00edos-C\u00e1rcamo","year":"2020","unstructured":"Berr\u00edos-C\u00e1rcamo P, Quezada M, Quintanilla ME, Morales P, Ezquer M, Herrera-Marschitz M, Israel Y, Ezquer F. Oxidative stress and neuroinflammation as a pivot in drug abuse. A focus on the therapeutic potential of antioxidant and anti-inflammatory agents and biomolecules. Antioxidants. 2020;9(9):830.","journal-title":"Antioxidants"},{"issue":"2","key":"8237_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.molmed.2017.12.009","volume":"24","author":"KJ Bough","year":"2018","unstructured":"Bough KJ, Pollock JD. Defining substance use disorders: the need for peripheral biomarkers. Trends Mol Med. 2018;24(2):109\u201320.","journal-title":"Trends Mol Med"},{"issue":"6","key":"8237_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1037\/a0029976","volume":"20","author":"DS Carson","year":"2012","unstructured":"Carson DS, Bosanquet DP, Carter CS, Pournajafi-Nazarloo H, Blaszczynski A, McGregor IS. Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users. Exp Clin Psychopharmacol. 2012;20(6):497.","journal-title":"Exp Clin Psychopharmacol"},{"key":"8237_CR20","doi-asserted-by":"publisher","first-page":"107807","DOI":"10.1016\/j.pharmthera.2021.107807","volume":"223","author":"N Morales-Puerto","year":"2021","unstructured":"Morales-Puerto N, Gimenez-Gomez P, P\u00e9rez-Hern\u00e1ndez M, Abuin-Martinez C, de Biedma-Elduayen LG, Vidal R, Guti\u00e9rrez-L\u00f3pez MD, O\u2019Shea E, Colado MI. Addiction and the kynurenine pathway: A new dancing couple? Pharmacol Ther. 2021;223:107807.","journal-title":"Pharmacol Ther"},{"key":"8237_CR21","doi-asserted-by":"publisher","first-page":"109958","DOI":"10.1016\/j.pnpbp.2020.109958","volume":"102","author":"R Vidal","year":"2020","unstructured":"Vidal R, Garc\u00eda-Marchena N, O\u2019Shea E, Requena-Oca\u00f1a N, Flores-L\u00f3pez M, Araos P, Serrano A, Su\u00e1rez J, Rubio G, de Fonseca FR. Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity. Prog Neuropsychopharmacol Biol Psychiatry. 2020;102:109958.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"8237_CR22","unstructured":"Karsten L. Tryptophan metabolism in the deer mouse and its response to serotonergic intervention. North-West University (South Africa); 2022."},{"key":"8237_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF02246547","volume":"122","author":"P Dingemans","year":"1995","unstructured":"Dingemans P, Linszen D, Lenior M, Smeets R. Component structure of the expanded brief psychiatric rating scale (BPRS-E). Psychopharmacology. 1995;122:263\u20137.","journal-title":"Psychopharmacology"},{"key":"8237_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12098-011-0517-7","volume":"79","author":"BK Patro","year":"2012","unstructured":"Patro BK, Jeyashree K, Gupta PK. Kuppuswamy\u2019s socioeconomic status scale 2010\u2014the need for periodic revision. Indian J Pediatr. 2012;79:395\u20136.","journal-title":"Indian J Pediatr"},{"key":"8237_CR25","unstructured":"Statistics South Africa. Census 2022 statistical release (P0301.4) [Internet]. Pretoria: Statistics South Africa; 2023. Available from: https:\/\/census.statssa.gov.za\/assets\/documents\/2022\/P03014_Census_2022_Statistical_Release.pdfStatistical"},{"issue":"3","key":"8237_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/17523280903192003","volume":"2","author":"M Hesse","year":"2009","unstructured":"Hesse M, Austin SF, Lykke IH Jr. Predictors of completing treatment and achieving abstinence during inpatient dual diagnosis treatment. Mental Health Subst Use: Dual Diagnosis. 2009;2(3):182\u201390.","journal-title":"Mental Health Subst Use: Dual Diagnosis"},{"key":"8237_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","volume":"24","author":"MW Jann","year":"1993","unstructured":"Jann MW, Grimsley SR, Gray EC, Chang W-H. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet. 1993;24:161\u201376.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"8237_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/0163-8343(89)90136-9","volume":"11","author":"LG Peterson","year":"1989","unstructured":"Peterson LG, Bongar B. Navane versus Haldol: Treatment of acute organic mental syndromes in the general hospital. Gen Hosp Psychiatry. 1989;11(6):412\u20137.","journal-title":"Gen Hosp Psychiatry"},{"key":"8237_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fpsyt.2013.00079","volume":"4","author":"JP Connor","year":"2013","unstructured":"Connor JP, Gullo MJ, Chan G, Young RM, Hall WD, Feeney GF. Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs. Front Psychiatry. 2013;4:79.","journal-title":"Front Psychiatry"},{"key":"8237_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jpsychires.2020.05.028","volume":"129","author":"S Madero","year":"2020","unstructured":"Madero S, Oliveras C, Pons M, Sague M, L\u00f3pez-Pelayo H, Gual A, Balcells M. Cannabis use the week before admission to psychiatric in-patient service as a marker of severity. J Psychiatr Res. 2020;129:40\u20136.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"8237_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0253-7176.155617","volume":"37","author":"R Parthasarathy","year":"2015","unstructured":"Parthasarathy R, Kattimani S, Sridhar M. Oxidative stress during alcohol withdrawal and its relationship with withdrawal severity. Indian J Psychol Med. 2015;37(2):175\u201380.","journal-title":"Indian J Psychol Med"},{"key":"8237_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2018.01.044","volume":"670","author":"GE Hirsch","year":"2018","unstructured":"Hirsch GE, Jaskulski M, Hamerski HM, Porto FG, da Silva B, Aita CAM, Kroker K, de Bem Silveira G, Silveira PCL, Santos GT. Evaluation of oxidative stress and brain-derived neurotrophic factor levels related to crack-use detoxification. Neurosci Lett. 2018;670:62\u20138.","journal-title":"Neurosci Lett"},{"key":"8237_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cotox.2020.04.003","volume":"20","author":"LR Pavlek","year":"2020","unstructured":"Pavlek LR, Dillard J, Rogers LK. The role of oxidative stress in toxicities due to drugs of abuse. Curr Opin Toxicol. 2020;20:29\u201335.","journal-title":"Curr Opin Toxicol"},{"issue":"2","key":"8237_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/0006-8993(92)91058-M","volume":"595","author":"BR Shivakumar","year":"1992","unstructured":"Shivakumar BR, Ravindranath V. Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res. 1992;595(2):256\u201362.","journal-title":"Brain Res"},{"issue":"20","key":"8237_CR35","doi-asserted-by":"publisher","first-page":"8236","DOI":"10.1523\/JNEUROSCI.18-20-08236.1998","volume":"18","author":"A Post","year":"1998","unstructured":"Post A, Holsboer F, Behl C. Induction of NF-\u03baB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-\u03baB and neuroprotection by antioxidants. J Neurosci. 1998;18(20):8236\u201346.","journal-title":"J Neurosci"},{"issue":"4","key":"8237_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.pbb.2004.05.018","volume":"78","author":"M Polydoro","year":"2004","unstructured":"Polydoro M, Schr\u00f6der N, Lima MNM, Caldana F, Laranja DC, Bromberg E, Roesler R, Quevedo J, Moreira JCF, Dal-Pizzol F. Haloperidol-and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav. 2004;78(4):751\u20136.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3\u20134","key":"8237_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0753-3322(03)00043-X","volume":"57","author":"DM Townsend","year":"2003","unstructured":"Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother. 2003;57(3\u20134):145\u201355.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"8237_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1096\/fasebj.13.10.1169","volume":"13","author":"SC Lu","year":"1999","unstructured":"Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999;13(10):1169\u201383.","journal-title":"FASEB J"},{"key":"8237_CR39","doi-asserted-by":"crossref","unstructured":"Shen W, Liu H, Xie X, Liu H, Zhou W. Biochemical diagnosis in substance and non-substance addiction. In: Substance and non-substance addiction. 2017. p. 169-202.","DOI":"10.1007\/978-981-10-5562-1_9"},{"issue":"5","key":"8237_CR40","first-page":"675","volume":"20","author":"I Liappas","year":"2006","unstructured":"Liappas I, Tzavellas EO, Kariyannis C, Piperi C, Schulpis C, Papassotiriou I, Soldatos CR. Effect of alcohol detoxification on serum S-100B levels of alcohol-dependent individuals. Vivo. 2006;20(5):675\u201380.","journal-title":"Vivo"},{"issue":"7","key":"8237_CR41","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/brain\/awf165","volume":"125","author":"A Petzold","year":"2002","unstructured":"Petzold A, Eikelenboom M, Gveric D, Keir G, Chapman M, Lazeron R, Cuzner M, Polman C, Uitdehaag B, Thompson E. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002;125(7):1462\u201373.","journal-title":"Brain"},{"issue":"3","key":"8237_CR42","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1111\/ejn.14163","volume":"50","author":"K Linker","year":"2019","unstructured":"Linker K, Cross S, Leslie F. Glial mechanisms underlying substance use disorders. Eur J Neurosci. 2019;50(3):2574\u201389.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"8237_CR43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1749-6632.2002.tb04175.x","volume":"965","author":"P Tagliaferro","year":"2002","unstructured":"Tagliaferro P, Vega MD, Evrard SG, Ramos AJ, Brusco A. Alcohol exposure during adulthood induces neuronal and astroglial alterations in the hippocampal CA-1 area. Ann N Y Acad Sci. 2002;965(1):334\u201342.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"8237_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.acthis.2009.11.001","volume":"113","author":"W Udomuksorn","year":"2011","unstructured":"Udomuksorn W, Mukem S, Kumarnsit E, Vongvatcharanon S, Vongvatcharanon U. Effects of alcohol administration during adulthood on parvalbumin and glial fibrillary acidic protein immunoreactivity in the rat cerebral cortex. Acta Histochem. 2011;113(3):283\u20139.","journal-title":"Acta Histochem"},{"key":"8237_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00406-010-0121-2","volume":"261","author":"D Wedekind","year":"2011","unstructured":"Wedekind D, Neumann K, Falkai P, Malchow B, Engel KR, Jamrozinski K, Havemann-Reinecke U. S100B and homocysteine in the acute alcohol withdrawal syndrome. Eur Arch Psychiatry Clin Neurosci. 2011;261:133\u20138.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"8237_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1369-1600.2006.00018.x","volume":"11","author":"M Walter","year":"2006","unstructured":"Walter M, Gerhard U, Gerlach M, Weijers HG, Boening J, Wiesbeck GA. CLINICAL STUDY: Cortisol concentrations, stress-coping styles after withdrawal and long\u2010term abstinence in alcohol dependence. Addict Biol. 2006;11(2):157\u201362.","journal-title":"Addict Biol"},{"issue":"11","key":"8237_CR47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/metabo14110611","volume":"14","author":"L Contella","year":"2024","unstructured":"Contella L, Farrell CL, Boccuto L, Litwin AH, Snyder ML. Impact of Substance use disorder on tryptophan metabolism through the kynurenine pathway: a narrative review. Metabolites. 2024;14(11):611.","journal-title":"Metabolites"},{"issue":"2\u20133","key":"8237_CR48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000017309","volume":"20","author":"B Poeggeler","year":"1998","unstructured":"Poeggeler B, Rassoulpour A, Guidetti P, Wu H-Q, Schwarcz R. Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum. Dev Neurosci. 1998;20(2\u20133):146\u201353.","journal-title":"Dev Neurosci"},{"key":"8237_CR49","doi-asserted-by":"crossref","unstructured":"Gil de Biedma-Elduayen L, Gim\u00e9nez-G\u00f3mez P, Morales-Puerto N, Vidal R, Del R\u00edo-Garc\u00eda \u00c1, N\u00fa\u00f1ez-, de la Calle C, Careaga L, Guti\u00e9rrez-L\u00f3pez MD, O\u2019Shea E, Colado MI. The kynurenine pathway as a potential link between ethanol-induced behavioral alterations and neuroinflammation. Frontiers in Pharmacology 2025, 16:1628527.","DOI":"10.3389\/fphar.2025.1628527"},{"issue":"1","key":"8237_CR50","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1038\/s41598-019-53312-0","volume":"9","author":"P Araos","year":"2019","unstructured":"Araos P, Vidal R, O\u2019Shea E, Pedraz M, Garc\u00eda-Marchena N, Serrano A, Su\u00e1rez J, Castilla-Ortega E, Ruiz JJ, Campos-Cloute R. Serotonin is the main tryptophan metabolite associated with psychiatric comorbidity in abstinent cocaine-addicted patients. Sci Rep. 2019;9(1):16842.","journal-title":"Sci Rep"},{"issue":"1","key":"8237_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41398-021-01610-5","volume":"11","author":"S Leclercq","year":"2021","unstructured":"Leclercq S, Schwarz M, Delzenne NM, St\u00e4rkel P, de Timary P. Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms. Translational Psychiatry. 2021;11(1):503.","journal-title":"Translational Psychiatry"},{"issue":"1","key":"8237_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.102.034439","volume":"303","author":"R Schwarcz","year":"2002","unstructured":"Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303(1):1\u201310.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"8237_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0165-1781(94)90003-5","volume":"54","author":"M Maes","year":"1994","unstructured":"Maes M, Scharp\u00e9 S, Meltzer HY, Okayli G, Bosmans E, D\u2019Hondt P, Bossche BV, Cosyns P. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 1994;54(2):143\u201360.","journal-title":"Psychiatry Res"},{"issue":"1\u20132","key":"8237_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jad.2006.07.013","volume":"98","author":"A-M Myint","year":"2007","unstructured":"Myint A-M, Kim YK, Verkerk R, Scharp\u00e9 S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98(1\u20132):143\u201351.","journal-title":"J Affect Disord"},{"issue":"2\u20133","key":"8237_CR55","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.psychres.2015.03.031","volume":"227","author":"KA Bradley","year":"2015","unstructured":"Bradley KA, Case JA, Khan O, Ricart T, Hanna A, Alonso CM, Gabbay V. The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Res. 2015;227(2\u20133):206\u201312.","journal-title":"Psychiatry Res"},{"key":"8237_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.psyneuen.2015.02.011","volume":"56","author":"J Dahl","year":"2015","unstructured":"Dahl J, Andreassen OA, Verkerk R, Malt UF, Sandvik L, Brundin L, Ormstad H. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers. Psychoneuroendocrinology. 2015;56:12\u201322.","journal-title":"Psychoneuroendocrinology"},{"key":"8237_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbi.2015.11.003","volume":"53","author":"TB Meier","year":"2016","unstructured":"Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, Bodurka J, Teague TK, Dantzer R, Savitz J. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav Immun. 2016;53:39\u201348.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"8237_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/schbul\/sbl033","volume":"33","author":"AC Chess","year":"2007","unstructured":"Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007;33(3):797\u2013804.","journal-title":"Schizophr Bull"},{"issue":"8","key":"8237_CR59","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/sj.npp.1300188","volume":"28","author":"PD Shepard","year":"2003","unstructured":"Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology. 2003;28(8):1454\u201362.","journal-title":"Neuropsychopharmacology"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08237-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08237-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08237-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T01:05:02Z","timestamp":1785978302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08237-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8237"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08237-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the North-West University Health Research Ethics Committee (NWU-HREC) of the Faculty of Health Sciences (ethics approval no. NWU-00449-20-A1). All participants provided written informed consent for participation in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"598"}}